LEADERSHIP

Developed and Optimized a CRISPR/Cas9-based gene editing system in hematopoietic stem cells when studied at Harvard and worked at BRL Medicine.

Led the world’s first CRISPR/Cas9 Gene editing clinical trial for patients with β0/β0 thalassemia in 2020. Two pediatric patients with β-thalassemia achieved transfusion independence following treatment in three years.

Co-founder, VP at BRL Medicine Postdoc at Harvard Medical School, Associate Professor at CASPhD (Biology) at Wuhan University.

Published gene editing articles in top journals: Nature Medicine (x3), Cell Stem Cell (x3), and Cell Research.

Emma brings to YolTech more than 10 years of experience in the pharmaceutical and biotechnology industry. Prior to YolTech, Emma spent more than five years working in mRNA/LNP drug product development, formulation development, process and analytical development, technical transfer, CMC strategy at Beam, Tessera and Providence Therapeutics.  

As chief development and technical officer at YolTech, Emma oversees platform and pipeline research activities and manages a multidisciplinary team in drug product development, CMC, manufacturing, regulatory affairs, quality and early clinical development. She holds a B.Eng and M.Eng in Chemical Engineering from McGill University in Canada and Ph.D in Chemistry from Max Planck Institute for Polymer Research in Germany. 

Gene Editing Technology Development and Platform Operation.

10 years+ experience in gene editing and base editing technology, successfully developed various gene editing methods with 6 patents.

Founder of BIOGLE Gene (CRO of Gene Editing).

PI of Shanghai Jiao Tong University.

Ph. D at Wuhan University.